Overview

• Capricor Q3 net loss widens to $24.6 mln, with no revenue generated

• Company prepares for Deramiocel launch in 2026, pending HOPE-3 study results

• Cash balance of $99 mln expected to support operations into Q4 2026

Outlook

• Capricor expects HOPE-3 Phase 3 study results in Q4 2025

• Company plans commercial launch of Deramiocel in 2026

• Capricor expects cash balance to support operations into Q4 2026

Result Drivers

• HOPE-3 RESULTS - Capricor anticipates topline results from HOPE-3 Phase 3 trial for Deramiocel in Q4 2025, which could lead to BLA resubmission

• COMMERCIAL PREPARATIONS - Capricor is preparing for potential Deramiocel launch in 2026, pending approval, with manufacturing readiness confirmed

• STEALTHX VACCINE TRIAL - Phase 1 trial of StealthX™ exosome-based vaccine ongoing, with initial data expected Q1 2026

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Capricor Therapeutics Inc is $21.50, about 72.4% above its November 7 closing price of $5.93

Press Release: ID:nGNX4Yc4K5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)